Alyeska Investment Group
IBER

Alyeska Investment Group’s Ibere Pharmaceuticals IBER Stock Holding History

Alyeska Investment Group’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150,000
Closed -$1.47M – 593
2022
Q2 		$1.47M Hold
150,000
– – 0.02% 439
2022
Q1 		$1.47M Hold
150,000
– – 0.02% 463
2021
Q4 		$1.46M Hold
150,000
– – 0.02% 486
2021
Q3 		$1.45M Hold
150,000
– – 0.02% 554
2021
Q2 		$1.45M Buy
+150,000
New +$1.46M 0.02% 556

Other funds holding IBER

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Alyeska Investment Group's IBER Position: Q3 2022 in Review

Alyeska Investment Group sold out of Ibere Pharmaceuticals (IBER) in Q3 2022, closing a stake of 150,000 shares — an estimated $1.47M sold.

Alyeska Investment Group first reported a position in IBER in Q2 2021 and held it in 5 quarters. The position peaked at $1.47M in Q2 2022. 48 funds tracked by Wall St. Rank hold IBER as of Q3 2022.

  • Alyeska Investment Group reported no remaining Ibere Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 150,000 Ibere Pharmaceuticals shares in Q3 2022, an estimated $1.47M.
  • Alyeska Investment Group first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Alyeska Investment Group's Ibere Pharmaceuticals position peaked at $1.47M in Q2 2022.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q3 2022.

Based on Alyeska Investment Group's 13F filing for Q3 2022, filed 14 Nov 2022.